Quarterly report pursuant to Section 13 or 15(d)

Business (Details)

v3.21.2
Business (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Jun. 04, 2021
USD ($)
shares
Jun. 11, 2020
USD ($)
shares
Jan. 31, 2021
USD ($)
shares
Sep. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
product
shares
Jun. 30, 2020
USD ($)
Jun. 30, 2021
USD ($)
product
Jun. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Subsequent Event [Line Items]                  
Cash and cash equivalents         $ 40,435 $ 45,391 $ 40,435 $ 45,391 $ 18,919
Sale of stock (in shares) | shares     13,971,889            
Net loss         (17,105) $ (13,281) (47,785) (34,398)  
Net cash used in operating activities             (37,503) $ (14,294)  
(Accumulated deficit) retained earnings         (225,575)   (225,575)   $ (177,790)
Underwritten Public Offering                  
Subsequent Event [Line Items]                  
Sale of stock (in shares) | shares   15,180,000 13,971,889            
Net proceeds   $ 35,400 $ 37,700            
Warrant                  
Subsequent Event [Line Items]                  
Sale of stock (in shares) | shares     1,676,923            
Forecast                  
Subsequent Event [Line Items]                  
Portion fundable upon achieving predetermined milestones       $ 5,000          
Horizon & Powerscourt Notes | Notes Payable                  
Subsequent Event [Line Items]                  
Cash and cash equivalents         40,400   40,400    
Principal amount $ 35,000       35,000   35,000    
Portion funded on the closing date 20,000       20,000   20,000    
Portion fundable upon achieving predetermined milestones $ 15,000       15,000   $ 15,000    
Proceeds from debt         $ 19,600        
Horizon & Powerscourt Notes | Notes Payable | Warrant                  
Subsequent Event [Line Items]                  
Sale of stock (in shares) | shares 403,844       403,844        
Horizon & Powerscourt Notes | Notes Payable | Forecast                  
Subsequent Event [Line Items]                  
Proceeds from debt       10,000          
Payments of debt issuance costs       1,700          
Proceeds from debt, net of issuance costs       $ 17,900          
Neurological Clinical and Preclinical Stage Compounds                  
Subsequent Event [Line Items]                  
Number of products in development | product         2   2    
Clinical Stage                  
Subsequent Event [Line Items]                  
Number of products in development | product         4   4